The Ottawa Hospital

Running trials

• Not yet recruiting

  SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy

  NCT07687160· Phase 4· Source

• Not yet recruiting

  Mycophenolate After Stem Cell Transplant for Systemic Sclerosis

  NCT07734012· Phase 2· Source

• Not yet recruiting

  Cardiac CT Angiography in Acute Stroke Imaging (SCOPE-CT)

  NCT07896889· Source

• Not yet recruiting

  Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma

  NCT07840443· Phase 2· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)

  NCT07372716· Source

• Recruiting

  Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough

  NCT06858748· Source

• Recruiting

  Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)

  NCT06983821· Phase 3· Source

• Not yet recruiting

  Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotics and Steroids?

  NCT06929767· Phase 4· Source

• Recruiting

  DIALysis With EXpanded Solute Removal

  NCT06660277· Source

• Recruiting

  Personalized Hypoglycemia Outpatient Treatment - a Feasibility Study

  NCT07094529· Source

• Recruiting

  Feasibility Trial for a Right Ventricular Failure Platform Trial

  NCT06570473· Phase 2· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease

  NCT06816810· Phase 2· Source

• Recruiting

  Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

  NCT06256575· Source

• Recruiting

  Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

  NCT06957366· Source

• Active, not recruiting

  MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

  NCT06586515· Phase 1· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Source

• Recruiting

  Pancreatic Insulin Production Capacity (PIPC) - a Feasibility Study

  NCT06462170· Source

• Active, not recruiting

  VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

  NCT06249555· Source

• Recruiting

  Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

  NCT06016387· Phase 2· Source

• Recruiting

  A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  NCT06131840· Phase 1· Source

• Recruiting

  Intensive Cancer Screening After Cryptogenic Stroke

  NCT05733416· Source

• Recruiting

  Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

  NCT05955924· Phase 3· Source

• Active, not recruiting

  A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver

  NCT05677113· Phase 2· Source

• Active, not recruiting

  A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

  NCT05781113· Source

• Active, not recruiting

  ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

  NCT05686317· Source

• Recruiting

  Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

  NCT05169112· Phase 3· Source

• Active, not recruiting

  A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

  NCT05481151· Phase 3· Source

• Active, not recruiting

  PRevEnting FracturEs in REnal Disease - 1

  NCT05096195· Phase 4· Source

• Recruiting

  The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III

  NCT04871412· Phase 3· Source

• Recruiting

  The DRAGON 2 Trial

  NCT05428735· Source

• Recruiting

  INPWT on Wound Complications & Clinical Outcomes After Lower Extremity Sarcoma Surgery Preop Radiation Therapy Patients

  NCT03175718· Source

• Recruiting

  Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)

  NCT06844227· Source

• Active, not recruiting

  Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis

  NCT04671862· Source

• Recruiting

  DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

  NCT07717437· Source

• Recruiting

  Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)

  NCT04574960· Phase 3· Source

• Recruiting

  Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

  NCT04335292· Phase 2· Source

• Active, not recruiting

  A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

  NCT04093349· Phase 1/2· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· Source

• Active, not recruiting

  Surveillance AFter Extremity Tumor surgerY

  NCT03944798· Source

• Active, not recruiting

  A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

  NCT04002297· Phase 3· Source

• Active, not recruiting

  Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

  NCT03836352· Phase 2· Source

• Active, not recruiting

  Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

  NCT03715478· Phase 1/2· Source

• Recruiting

  International Severe Asthma Registry: Canadian Cohort

  NCT04045587· Source

• Active, not recruiting

  A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

  NCT03589326· Phase 3· Source

• Active, not recruiting

  Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections

  NCT03651154· Source

• Recruiting

  HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

  NCT02855476· Source

• Recruiting

  Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

  NCT02869802· Source

• Recruiting

  REtroperitoneal SArcoma Registry: an International Prospective Initiative

  NCT03838718· Source

Showing 50 of 53.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation3 recruiting
• Lung cancer3 recruiting
• Asthma2 recruiting
• Colorectal cancer2 recruiting
• COPD2 recruiting
• Gastric and oesophageal cancer2 recruiting
• High blood pressure2 recruiting
• Huntington's disease2 recruiting
• Liver and biliary tract cancer2 recruiting
• Sarcoma2 recruiting
• Stroke2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Type 2 diabetes2 recruiting
• ANCA-associated vasculitis1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Heart failure1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

  NCT05849129· Phase 2· Source

• Completed

  RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

  NCT05513560· Phase 2/3· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Source

• Completed

  Study of WVE-003 in Patients With Huntington's Disease

  NCT05032196· Phase 1/2· Source

• Completed

  An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

  NCT04564079· Source

• Completed

  Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

  NCT04243122· Phase 2· Source

• Terminated

  HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

  NCT04684914· Phase 2· Source

• Completed

  Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT03781063· Phase 2· Source

• Completed

  I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

  NCT03939689· Phase 2· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Source

• Terminated

  WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

  NCT03297359· Phase 2· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Source

• Completed

  A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

  NCT03332017· Phase 2· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source